Shots:

• The 1st patients have been dosed in a P-III study & long-term safety trial to evaluate the safety & efficacy of brilaroxazine (15/50mg, qd for 28 days) vs PBO in ~400 patients with schizophrenia. The study will further assess the safety & tolerability of an OLE treatment for 52wks.
• In a P-II study, brilaroxazine showed a reduction in PANSS total score, improvements for 2EPs of social functioning, symptoms, depression & cognition, no weight gain & increase in blood sugar & lipids, no cardiac or endocrine AEs
• The company is planning to expand clinical development of brilaroxazine into indications including bipolar disorder, MDD &  ADHD in 2022, based on the P-II study in schizophrenia

Ref: Globe Newswire | Image: Businesswire